Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Stressor-Focused Therapy for Emotional Processing in Adjustment Disorder (STEP)

14 novembre 2026 mis à jour par: Rahel Bachem

STEP - Stressor-focused Therapy for Emotional Processing in ICD-11 Adjustment Disorder: A Randomised Waitlist-Controlled Trial

This randomized controlled trial evaluates the efficacy of STEP, a brief 12-session psychotherapy for adults with ICD-11 Adjustment Disorder (AjD). STEP is a manualized, CBT-based, event-focused intervention designed to reduce Adjustment Disorder symptoms and support adaptive emotional processing and coping. Participants in the waitlist control group will receive STEP after the 12-week waiting period. Outcomes will be assessed at baseline, post-treatment, and at a 3-month follow-up. The primary outcome is Adjustment Disorder symptom severity. Secondary outcomes include perceived stress, depression, anxiety, well-being, and experiential avoidance.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

Adjustment disorder (AjD) is characterised in ICD-11 by two core symptom clusters: preoccupation with the stressor and failure to adapt. Although adjustment disorder is frequently diagnosed in clinical practice, evidence for disorder-specific psychological treatments based on the ICD-11 conceptualisation remains limited.

STEP (Stressor-focused Therapy for Emotional Processing) was developed to address these core symptoms through a structured, event-focused cognitive-behavioural approach. The treatment is based on the conceptualisation of adjustment disorder as a stress-response syndrome, in which persistent preoccupation with a stressful life event and avoidance of associated memories, thoughts, and emotions may contribute to symptom maintenance.

Drawing on established cognitive-behavioural and trauma-focused treatment principles, STEP integrates psychoeducation, individual case formulation, emotional awareness and regulation, event-focused imaginal exposure, cognitive restructuring, resource activation, and adaptive coping strategies. A central component is the guided emotional processing of distressing life events and emotionally salient moments associated with the stressor. The intervention aims to reduce maladaptive avoidance and preoccupation, facilitate emotional processing, and support adaptation to changed life circumstances.

This randomised waitlist-controlled trial evaluates the efficacy of STEP in adults diagnosed with ICD-11 adjustment disorder. The primary hypothesis is that participants receiving STEP will demonstrate greater reductions in adjustment disorder symptoms than participants assigned to the waitlist condition. Secondary objectives include examining changes in psychological distress, experiential avoidance, and subjective well-being, as well as evaluating treatment feasibility and acceptability.

The study is expected to contribute to the development of targeted, evidence-based psychotherapeutic interventions for adjustment disorder.

Type d'étude

Interventionnel

Inscription (Estimé)

70

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Rahel Bachem, Prof. Dr.
  • Numéro de téléphone: +41 58 257 35 26
  • E-mail: rahel.bachem@ost.ch

Lieux d'étude

    • Canton of St. Gallen
      • Sankt Gallen, Canton of St. Gallen, Suisse, 9001
        • Competence Center for Mental Health; Eastern Switzerland University of Applied Sciences
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age ≥ 18 years
  • Diagnosis of ICD-11 Adjustment Disorder confirmed via structured clinical interview using the IADQ diagnostic algorithm
  • Presence of a clearly identifiable psychosocial stressor 2 weeks to 2 years before participation
  • Sufficient German language proficiency to participate in psychotherapy and complete study assessments
  • Capacity to provide written informed consent

Exclusion Criteria:

  • Current PTSD or CPTSD meeting ICD-11 diagnostic criteria following a Criterion A traumatic event
  • Current prolonged grief disorder meeting ICD-11 diagnostic criteria
  • Lifetime history of bipolar disorder or psychotic disorder, including schizophrenia spectrum disorders
  • Severe depressive or anxiety symptoms clearly predating the identified stressor and judged to better account for the current clinical presentation
  • Another severe mental disorder that would interfere with participation in psychotherapy or better explain the presenting symptoms
  • Acute suicidality requiring immediate crisis intervention
  • Ongoing psychotherapy

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: STEP Intervention Group

Participants assigned to the intervention group receive 12 weekly sessions of the STEP psychotherapy intervention after completion of the baseline assessment.

STEP is a brief, manualized, 12-session CBT-based psychotherapy specifically developed for ICD-11 Adjustment Disorder (AjD). It follows a staged, event-focused approach targeting the core symptom clusters of preoccupation and failure to adapt. Treatment components include psychoeducation and individualized case conceptualization, emotional awareness and regulation skills, stressor-focused imaginal exposure and emotional processing, cognitive and emotional reprocessing of stressor-related meanings, strengthening of personal resources and adaptive coping strategies, and relapse prevention.

Autre: Waitlist Control Group

Participants assigned to the waitlist control group do not receive the STEP intervention during the 12-week waiting period. After completion of the waiting period, participants receive the STEP intervention.

STEP is a brief, manualized, 12-session CBT-based psychotherapy specifically developed for ICD-11 Adjustment Disorder (AjD). It follows a staged, event-focused approach targeting the core symptom clusters of preoccupation and failure to adapt. Treatment components include psychoeducation and individualized case conceptualization, emotional awareness and regulation skills, stressor-focused imaginal exposure and emotional processing, cognitive and emotional reprocessing of stressor-related meanings, strengthening of personal resources and adaptive coping strategies, and relapse prevention.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Adjustment Disorder Symptom Severity at Post-Treatment
Délai: Week 12-14 after baseline (T1; post-treatment in the immediate intervention group and post-waiting period in the control group)

Adjustment disorder symptom severity is assessed using the International Adjustment Disorder Questionnaire (IADQ). The primary outcome is the sum of six symptom items (Items 1-6), covering preoccupation with the stressor and failure to adapt. Each item is rated from 0 to 4, resulting in a total score ranging from 0 to 24, with higher scores indicating greater symptom severity. Scores at T1 will be compared between groups, adjusting for baseline scores.

Week 12-14 after baseline (T1; post-treatment in the immediate intervention group and post-waiting period in the control group)
Depressive Symptom Severity
Délai: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the International Depression Questionnaire (IDQ), measuring depressive symptoms according to ICD-11.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Anxiety Symptom Severity
Délai: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the International Anxiety Questionnaire (IAQ), measuring symptoms of generalized anxiety according to ICD-11.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Perceived Stress
Délai: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the 10-item Perceived Stress Scale (PSS-10), measuring the perceived level of stress.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Subjective Well-Being
Délai: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the World Health Organization-Five Well-Being Index (WHO-5), measuring subjective psychological well-being.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Experiential Avoidance
Délai: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the Brief Experiential Avoidance Questionnaire (BEAQ), measuring the tendency to avoid unwanted internal experiences.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Adjustment Disorder Diagnostic Status
Délai: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed through a structured clinical interview evaluating the presence or absence of ICD-11 adjustment disorder and diagnostic remission.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Treatment Credibility and Expectancy
Délai: Immediately after STEP Session 1

Assessed using the Credibility/Expectancy Questionnaire (CEQ), measuring treatment credibility and expected improvement.

Immediately after STEP Session 1
Treatment Acceptability and Feasibility
Délai: Immediately after completion of the 12-session STEP treatment

Assessed using the Treatment Feedback and Adherence questionnaire (TFA), evaluating participants' experiences with STEP.

Immediately after completion of the 12-session STEP treatment
Event-Focused Repetitive Thoughts
Délai: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the Event-focused Repetitive Thoughts Questionnaire (ERTQ), measuring repetitive thoughts related to stressful life events.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 janvier 2027

Achèvement primaire (Estimé)

1 mars 2029

Achèvement de l'étude (Estimé)

1 mai 2029

Dates d'inscription aux études

Première soumission

14 novembre 2026

Première soumission répondant aux critères de contrôle qualité

14 novembre 2026

Première publication (Réel)

19 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

14 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • STEP_PILOTSTUDY
  • PT0041_222855 (Autre subvention/numéro de financement: Swiss National Science Foundation - SNSF)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

A fully anonymized individual participant dataset will be made available in a publicly accessible scientific repository (e.g., OSF) following publication of the primary study results. All direct identifiers will be removed, and indirect identifiers will be minimized to prevent re-identification. No identifiable or coded participant data will be shared.

Délai de partage IPD

The anonymized individual participant dataset will become publicly available following publication of the primary study results. The dataset will remain accessible for as long as it is maintained in the selected public scientific data repository.

Critères d'accès au partage IPD

The fully anonymized dataset will be publicly accessible to researchers and other interested users through an open scientific data repository, such as the Open Science Framework (OSF), without an individual access request. The shared dataset will contain numerical questionnaire data and broadly categorized demographic information. Free-text descriptions, exact age, geographical information, direct identifiers, and coded participant data will not be made publicly available. A data dictionary will accompany the dataset.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .